Cadila, SIFI to market Innovative Intraocular Lenses

Zydus Cadila and global Pharma major SIFI announced that they have tied-up to market innovative IOLs (Intraocular lenses) and surgical products developed in Italy and licensed in India by SIFI to treat ophthalmic disorders in the Indian market.

Zydus and SIFI are planning to bring this innovation to India and the South Asia region to provide eye surgeons with advanced technology and consequently yield better quality of vision and life of patients.

Cadila Healthcare's FY18 revenue mix comprised US Formulations (50 per cent), India Formulations (29 per cent), EMB Formulations (6 per cent), Animal Health (4 per cent), Wellness (4 per cent), API (3 per cent), Alliances (2 per cent) and Europe Formulations (2 per cent).

During the recently concluded quarter Q3FY19, the company has witnessed 10 per cent yoy increase in its revenue. However, the bottomline declined by 6 per cent on yoy basis.

On Tuesday, the stock of Cadila Healthcare opened at Rs. 330.85 per share and made an intraday low of Rs. 321.35 on the BSE. At 11:17 hours, the stock was trading nearly at Rs. 322.20 on the BSE. The company had hit its 52-week high of Rs. 432.40 on September 10, 2018 and its 52-week low of Rs. 306.35 on February 15, 2019 on the BSE.